Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792638 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL13849179 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL13849178 | 0.92 | LGALS3 (0.59) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL12792627 | 0.89 | LGALS3 (0.67) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL24299984 | 0.88 | MAPK1 (0.61) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL24917470 | 0.87 | MAPK1 (0.67) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL26989024 | 0.86 | MAPK1 (0.47) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14530114 | 0.86 | LGALS3 (0.63) | MAPK1ALDH1A1THRBCD69LGALS8 | |
| SCHEMBL13702248 | 0.86 | LGALS3 (0.63) | MAPK1ALDH1A1THRBCD69LGALS8 | |
| SCHEMBL25344300 | 0.85 | MAPK1 (0.71) | MAPK1ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | MAPK1 2363/4885ALDH1A1 1363/4885THRB 879/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | MAPK1 3714/4885ALDH1A1 3256/4885THRB 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.